EPA MInds Online n°7
European Psychiatric Association

2nd EPA Academia Faculty Workshop

Following the succes of the 1st EPA Academia Faculty Workshop held in November 2010, the EPA Committee on Education, chaired by Prof. Henning Sass, EPA Secretary for Education, decided to continue this important initiative aimed at providing effective and high quality CME courses during the annual European Congress of Psychiatry.

Therefore, the 2nd EPA Academia Faculty Workshop took place on 14 October 2011 in the EPA Headquarters in Strasbourg, France, and gathered in a friendly and constructive atmosphere the directors and co-directors of the EPA CME courses that will be organised at the 20th European Congress of Psychiatry in Prague March 2012.

The main objective of the 2nd Faculty Workshop was to elaborate on how to increase the effectiveness of the CME courses evaluation process. As a result of vivid dicussions, some guidelines were agreed, which will be further submitted to the EPA Committee on Education for approval.

Last call for applications

EPA Scholarship programme ensures the continuity of professional support to highly promising trainees and to start building European networks of which the scholars can take advantages in a life-long way.
Applications to the EPA Scholarship Programme close Monday 7 November. LEARN MORE

EPA grants Research Prizes of € 2,500 each to early career psychiatrists working in Europe, who have published the best scientific papers in the year 2011. Applications to the EPA Research Prizes close Monday 14 November. LEARN MORE

All applications will now have to be made exclusively online at :

EMA draft guideline consultation

The European Medicines Agency (EMA) has recently published a Draft Guideline on clinical investigation of medicinal products in the treatment of depression.

This document should be considered as general guidance on the development for medicinal products for acute and long-term treatment of major depression. Its main focus is on unipolar major depressive episodes. Despite many approved antidepressants there is still a need for new medicinal products with better efficacy (e.g. faster onset of action, higher rates of response and remission) and improved safety profile in patients with major depressive episodes.

The document is available for consultation by clicking HERE.
Copyright © 2011 European Psychiatric Association, All rights reserved.